Stock Price Forecast

May 4, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Jounce Therapeutics Inc chart...

About the Company

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

CEO

Richard Murray

Exchange

NASDAQ

Website

jouncetx.com

$25M

Total Revenue

141

Employees

$97M

Market Capitalization

-1.18

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $JNCE News

Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

11mon ago, source: Hosted on MSN

Boxed, Inc. (NYSE: BOXD) shares fell 9.8% to $ ... get started now. This article Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ...

Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

1y ago, source: Hosted on MSN

Vacasa, Inc. (NASDAQ: VCSA ... get started now. This article Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket originally appeared on ...

Gilead licenses Jounce immunotherapy for $800m

3y ago, source: pharmaphorum

Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million. The drug, JTX-1811, is a monoclonal antibody designed to ...

Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb

3y ago, source: ADVFN

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has ...

Redx and Jounce Announce Recommended Business Combination

28d ago, source: ADVFN

Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007 ...

Kintara Therapeutics Inc KTRA

15h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

Intellia Therapeutics Inc NTLA

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Redx Pharma Regulatory News

20d ago, source: London South East

Inc 22nd Mar 2023 2:20 pm RNS Form 8.3 - Jounce Therapeutics, Inc 20th Mar 2023 3:00 pm RNS Form 8.3 - Jounce Therapeutics, Inc 20th Mar 2023 10:38 am RNS Form 8.5 (EPT/RI) 16th Mar 2023 9:48 am ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

23d ago, source: Yahoo Finance

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to US$26.10 in the week after its latest full-year results.

KROS Keros Therapeutics, Inc.

5d ago, source: Seeking Alpha

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...